<DOC>
	<DOCNO>NCT01889992</DOCNO>
	<brief_summary>Cardiac allograft remodel cause poor quality life , allograft failure increase mortality heart transplantation . Risk factor cardiac allograft remodel progression poorly define need effective interventions.This multi-factorial phenomenon , associate various immunological non-immunological factor . Animal study suggest M-TOR inhibition attenuate cardiac allograft remodel secondary down-regulation M-TOR downstream target increase autophagy . There paucity data regard effect Sirolimus , M-TOR inhibitor , human heart remodel . This aim proposal identify prevalence cardiac allograft remodel current immunosuppressive strategy determine risk factor development . It also identify molecular pathway associate cardiac allograft remodel determine impact Sirolimus pathway .</brief_summary>
	<brief_title>Cardiac Allograft Remodeling Effects Sirolimus</brief_title>
	<detailed_description>Heart transplantation become well-established treatment option patient end-stage heart disease currently one-year survival rate 90 % , five-year survival rate 70 % , 10-year survival rate 50 % . The introduction anti-rejection treatment thirty year ago drug know calcineurin inhibitor result significant improvement survival heart transplant recipient . However , improvement occurs first year transplantation . Beyond first year , mortality rate heart transplant recipient change , indicate cause late complication affect last three decade improvement post-transplant care . It become apparent order improve late outcome , focus heart transplant research need shift prevention treatment late complication . Cardiac allograft remodeling ( CAR ) , change heart 's geometric pattern , one common complication heart transplantation often inflict poor quality life , heart failure , decrease survival . The risk factor mechanism development progression CAR poorly define , effective treatment condition . In proposed study , identify prevalence , risk factor , effect CAR physical capacity , cardiac vascular disease , patient survival heart transplant . For assessment heart geometry , use cardiac magnetic resonance imaging ( CMRI ) , technique use visualize internal structure body detail . CMRI consider `` gold standard '' evaluate heart 's structure function . We also evaluate molecular genetic marker associate development progression CAR heart transplantation . The drug Sirolimus , new anti-rejection agent , use place calcineurin inhibitor heart transplantation . Recent experimental animal study indicate Sirolimus attenuate change heart 's geometry transplant ( i.e. , CAR ) improve heart function . We assess effect Sirolimus CAR human evaluate molecular genetic marker associate effect . It goal provide important insight nature CAR heart transplantation response new anti-rejection drug Sirolimus . This information significant impact treatment heart transplant recipient thus improve quality life prolong survival heart transplantation .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomegaly</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>All adult cardiac transplant recipient undergoing heart transplantation UNMC/TNMC . Adult cardiac transplant recipient acute rejection ( ISHLT R &gt; grade 2 ) acute infection .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Heart transplantation</keyword>
	<keyword>Cardiac allograft remodel</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Cardiac MRI</keyword>
	<keyword>M-TOR inhibitor</keyword>
</DOC>